Cardiff Oncology Inc (FRA:XE7C)

€ 4.05 -0.145 (-3.46%) Market Cap: 271.75 Mil Enterprise Value: 218.07 Mil PE Ratio: 0 PB Ratio: 4.20 GF Score: 53/100

Q2 2024 Cardiff Oncology Inc Earnings Call Transcript
Aug 08, 2024

€1.88 (-5.54%)

Earnings
Q1 2024 Cardiff Oncology Inc Earnings Call Transcript
May 02, 2024

€3.87 (-5.39%)

Earnings
Q4 2023 Cardiff Oncology Inc Earnings Call Transcript
Feb 29, 2024

€1.64 (+2.24%)

Earnings
Q3 2023 Cardiff Oncology Inc Earnings Call Transcript
Nov 02, 2023

€1.01 (+2.44%)

Earnings
Cardiff Oncology Inc Clinical Update Call Transcript
Sep 26, 2023
Cardiff Oncology Inc Clinical and Corporate Update Call Transcript
Aug 07, 2023
Cardiff Oncology Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel Transcript
Mar 07, 2023
Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) Transcript
Dec 07, 2022
Cardiff Oncology Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Cardiff Oncology Inc to Provide a Clinical and Corporate Update Call Transcript
Sep 12, 2022
Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI Transcript
Jan 18, 2022
Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar Transcript
Sep 08, 2021
Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Cardiff Oncology Inc KOL Webinar Transcript
Apr 12, 2021
Cardiff Oncology Inc Discusses KRAS Mutations in Cancer Transcript
Oct 14, 2020
Cardiff Oncology, Inc. - Special Call Transcript
Sep 23, 2020
Cardiff Oncology Inc Onvansertib Clinical Trials Transcript
May 18, 2020
Trovagene Inc at Needham Healthcare Conference Transcript
Apr 15, 2020
Trovagene Inc Business Update Conference Call Transcript
Jun 07, 2019

Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) Transcript

Jul 15, 2021 / 04:00PM GMT

Release Date Price: €4.96 (-6.42%)

Transcript

Andy Hsieh

William Blair & Company - Analyst

So this is our second day of the Biotech Focus Conference. So we are really privileged to have the CEO of Cardiff Oncology, Mark Erlander, to give us a little debrief about the progress that you've made. Obviously the KRAS space is really hot, and it seems like the activity of this compound has pan-cancer activity. So we're really excited to hear what you have to say. But before we do that, I have to disclose that for a full list of conflicts and disclosures, please go to our website, WilliamBlair.com, for a list of full disclosures.

Questions & Answers

Andy Hsieh

William Blair & Company - Analyst

So to start off, Mark, maybe it's been a great year for the Company. So maybe reflect on the past year and highlight some points for us, all the accomplishments, and what are you looking forward to in the next year, year and a half for the Company?

Mark Erlander

Cardiff Oncology, Inc. - CEO

Thank you. Thank you, Andy. And look, we are absolutely thrilled to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.